



State of Missouri Medicaid Helpdesk Status Report

SUBJECT: May 1, 2011 - May 31, 2011

DATE: June 1, 2011

CLINICAL EDIT/PRIOR AUTHORIZATION PROGRAM OVERVIEW

Helpdesk Transactions	Total
<i>Total Helpdesk Transaction Count</i>	11,804
<i>Total Approved Claims at Helpdesk</i>	8,866
<i>Total Denied Claims at Helpdesk</i>	2,938
<i>Total number of transactions completed by InfoX PA staff</i>	11,447
<i>Total number of transactions completed by the State PA staff</i>	358

CLINICAL EDIT/PRIOR AUTHORIZATION TRANSACTION COUNTS

Drug Class	Helpdesk Approved	Helpdesk Denied	Helpdesk Total
NEW DRUG - MISSOURI	484	41	525
5HT3 RECEPTOR	1	0	1
ACCUTANE	86	0	86
ACTIQ	2	0	2
ADHD	1,251	46	1,297
ALINIA	2	0	2
AMITIZA	28	7	35
ANTIBIOTIC PAK	55	27	82
ANTIPLATELET	67	10	77
BIDIL	1	3	4
BOTOX	44	1	45
COLD SORE	8	28	36
COUGH AND COLD	2	3	5
COX-2	55	24	79
DIFLUCAN	21	30	51
EMEND	1	0	1
EPOETIN	6	0	6
EQUETRO	6	0	6
FORTEO	1	1	2

Drug Class	Helpdesk Approved	Helpdesk Denied	Helpdesk Total
GARDASIL	13	0	13
GENERIC OVERRIDES	18	0	18
GEODON INJ	4	0	4
GROWTH HORMONES	4	1	5
H PYLORI	29	9	38
H2 ANTAGONISTS	94	73	167
HYDROXYPROGESTERONE CAPROATE P	2	0	2
KLONOPIN WAFER	13	2	15
LACTULOSE	84	26	110
LYRICA	126	99	225
MEGESTROL	20	18	38
METHADONE	27	0	27
MIRALAX	467	126	593
MODAFINIL	12	0	12
NPD-2ND GENERATION ANTIHISTAMINES	219	166	385
NPD-ACE CCB COMBINATIONS	4	2	6
NPD-ACE INHIBITORS	14	11	25
NPD-ALZHEIMERS AGENTS	3	1	4
NPD-ANGIOTENSIN II REC/CCB COMBO	3	2	5
NPD-ANGIOTENSIN II RECEPTOR BLOCKERS	8	3	11
NPD-ANTIFUNGAL	5	12	17
NPD-BETA ADRENERGIC-NEBULIZED	56	13	69
NPD-BETA BLOCKERS	17	20	37
NPD-BIGUANIDES	0	2	2
NPD-BONE DEOSSIFICATION	15	15	30
NPD-CCB - DHP	2	2	4
NPD-CCB - NONDHP	0	3	3
NPD-COPD ANTICHOLINERGICS	4	5	9
NPD-DMARDS	22	4	26
NPD-DPP IV INHIBITORS	5	12	17
NPD-ELECTROLYTE DEPLETERS	11	18	29
NPD-FLUOROQUINOLONES	82	63	145
NPD-HERPES ANTIVIRALS	1	0	1
NPD-HMG	54	21	75
NPD-INHALED CORTICOSTEROIDS	14	14	28
NPD-INSULINS	2	0	2
NPD-INSULINS - RAPID ACTING	7	2	9
NPD-INTRANASAL ANTIHISTAMINE	21	34	55

Drug Class	Helpdesk Approved	Helpdesk Denied	Helpdesk Total
NPD-INTRANASAL STEROIDS	10	24	34
NPD-LIPOTROPICS	1	2	3
NPD-LONG ACTING NARCOTICS	268	12	280
NPD-LOW MOLECULAR WEIGHT HEPARINS	7	1	8
NPD-MACROLIDES	39	11	50
NPD-NON ERGOT DOPAMINE RECEPTOR AGONISTS	2	2	4
NPD-OPHTHALMIC ANTIHISTAMINES	1	17	18
NPD-OPHTHALMIC NSAIDS	0	6	6
NPD-OPHTHALMIC QUINOLONE	2	21	23
NPD-ORAL PULMONARY HYPERTENSION	0	3	3
NPD-OTIC QUINOLONE	0	15	15
NPD-PLATELET INHIBITOR AGENT	11	7	18
NPD-PPI	484	359	843
NPD-PULMONARY HTN	1	0	1
NPD-RIBAVIRINS	0	1	1
NPD-SEDATIVE HYPNOTICS	19	38	57
NPD-SKELETAL MUSCLE RELAXANTS	11	140	151
NPD-TOPICAL ANDROGENIC AGENTS	0	3	3
NPD-TOPICAL BENZOYL COMB	3	5	8
NPD-TOPICAL PSORIASIS	7	3	10
NPD-TOPICAL RETINOID	11	29	40
NPD-TRAMADOL	166	135	301
NPD-TRIGLYCERIDE LOWERING AGENTS	16	56	72
NPD-TRIPTANS	59	25	84
NPD-ULCERATIVE COLITIS ORAL	1	3	4
NPD-URINARY TRACT ANTISPASMODICS	3	19	22
NPD-VAGINAL ANTIBIOTICS	0	7	7
NSAID - NON-SELECTIVE	149	197	346
ORLISTAT [XENICAL]	0	2	2
OTC	2	0	2
OXANDRIN	1	0	1
PDL-ANGIOTENSIN II REC/CCB COMBO	1	0	1
PDL-ANTIDIABETIC COMBINATION	4	1	5
PDL-ANTIFUNGAL	24	23	47
PDL-CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME	1	0	1
PDL-DIRECT RENIN	6	0	6
PDL-DMARDS	7	1	8

Drug Class	Helpdesk Approved	Helpdesk Denied	Helpdesk Total
<i>PDL-DPP IV INHIBITORS</i>	22	12	34
<i>PDL-FIBROMYALGIA</i>	420	40	460
<i>PDL-GLP-1 RECEPTOR AGONISTS</i>	1	0	1
<i>PDL-INTRANASAL ANTIHISTAMINE</i>	3	7	10
<i>PDL-INTRANASAL STEROIDS</i>	1	0	1
<i>PDL-LONG ACTING NARCOTICS</i>	81	1	82
<i>PDL-MACROLIDES</i>	1	0	1
<i>PDL-PPI</i>	440	92	532
<i>PDL-SEDATIVE HYPNOTICS</i>	128	0	128
<i>PDL-SKELETAL MUSCLE RELAXANTS</i>	9	245	254
<i>PDL-TOPICAL RETINOID</i>	115	23	138
<i>PDL-TRAMADOL</i>	14	10	24
<i>PDL-TRIPTANS</i>	247	74	321
<i>PDL-ULCERATIVE COLITIS ORAL</i>	5	3	8
<i>PPI</i>	4	0	4
<i>REVATIO</i>	5	0	5
<i>SELZENTRY</i>	12	0	12
<i>SSRI</i>	2,028	203	2,231
<i>SUBUTEX_SUBOXONE</i>	135	1	136
<i>SUCRALFATE</i>	57	47	104
<i>TCA</i>	135	0	135
<i>THIAZOLIDINEDIONES</i>	28	3	31
<i>TINDAMAX</i>	4	2	6
<i>VIVITROL</i>	12	3	15
<i>VORICONAZOLE</i>	7	1	8
<i>XANAX XR</i>	8	2	10
<i>XOLAIR</i>	18	0	18
<i>ZOMETA</i>	0	1	1
<i>ZYPREXA</i>	6	0	6

Utilization Indicators	Total
<i>Average number of transactions per day</i>	381
<i>Override approval rate for clinical edits</i>	75.1 %

EARLY REFILL, DOSE OPTIMIZATION, HOSPICE, 15-DAY LIMITATION, AND EXCEPTION 716 PROGRAM OVERVIEW

Helpdesk Transactions	Total
<i>Total Helpdesk Transaction Count</i>	4,408
<i>Total Approved Claims at Helpdesk</i>	4,356
<i>Total Denied Claims at Helpdesk</i>	52
<i>Total number of transactions completed by InfoX PA staff</i>	4,329
<i>Total number of transactions completed by the State PA staff</i>	79

Early Refill	Total
<i>Early Refill Authorization Requests</i>	3,139
<i>Early Refill Approvals</i>	3,082
<i>Approvals Due to Vacation Supply</i>	248
<i>Approvals Due to Lost Prescription</i>	685
<i>Approvals Due to Therapy Change</i>	1,044
<i>Approvals Due to Starter Dose</i>	0
<i>Approvals Due to Medically Necessary</i>	1,105
<i>Early Refill Administrative Approvals</i>	7
<i>Early Refill Denials</i>	50

Dose Optimization	Total
<i>Dose Optimization Authorization Requests</i>	1,239
<i>Dose Optimization Approvals</i>	1,237
<i>Dose Optimization Denials</i>	2

Exception 716 Override	Total
<i>Drug Approval for larger quantities</i>	1
<i>Drug Denial for larger quantities</i>	0

Exception 713 Override	Total
<i>Drug Not Related to Terminal Illness - Approved</i>	1
<i>Drug Related to Terminal Illness - Denied</i>	0

Exception 712 Override	Total
<i>Drug Therapy Approved for > 15 Days</i>	15
<i>Drug Therapy Denied for > 15 Days</i>	0

Early Refill, Dose Optimization, Exceptions 716, 713, and 712 Utilization Indicators	Total
<i>Average number of transactions per day</i>	142.2
<i>Override approval rate for ER and Dose Opt edits</i>	99 %